Home Page Overall Ranking ROE Ranking P/E Ranking Dividend Yield Capitalization Our eBook Our Book Contact










Isin US1510201049
Ticker CELG
Company CELGENE
Currency $
Price
Aware Investor Index (AII) 0.5719
Recommendation BUY
P/E 54.78
ROE 18.62 %
Capitalization 70,599,510,000 $
Dividend Yield 0.00 %
P/S 5.43
AII Position 313
P/E Position 627
ROE Position 170
Capitalization Position 116
Dividend Yield Position 596
Sales 13,003,000,000 $
10-Year Average Earnings 1,288,873,600 $
Shares Outstanding 808,700,000
Equity 6,921,000,000 $
Dividend per Share 0 $
Industry Biotechnology
Country United States
CELGENE Investor Relations Web Site http://ir.celgene.com







Sales:

YEAR MONTH AMOUNT
2017 12 13,003,000,000.00 $
2016 12 11,229,000,000.00 $
2015 12 9,256,000,000.00 $
2014 12 7,670,400,000.00 $
2013 12 6,493,900,000.00 $

Earnings:

YEAR MONTH AMOUNT
2017 12 2,940,000,000.00 $
2016 12 1,999,000,000.00 $
2015 12 1,602,000,000.00 $
2014 12 1,999,900,000.00 $
2013 12 1,449,900,000.00 $
2012 12 1,456,180,000.00 $
2011 12 1,318,150,000.00 $
2010 12 880,512,000.00 $
2009 12 776,747,000.00 $
2008 12 -1,533,653,000.00 $

Equity:

YEAR MONTH AMOUNT
2017 12 6,921,000,000.00 $
2016 12 6,600,000,000.00 $
2015 12 5,919,000,000.00 $
2014 12 6,524,800,000.00 $
2013 12 5,589,900,000.00 $
2012 12 5,694,467,000.00 $
2011 12 5,512,727,000.00 $

Shares Outstanding:

YEAR MONTH AMOUNT
2017 12 808,700,000
2016 12 803,300,000
2015 12 824,900,000
2014 12 836,000,000
2013 12 430,300,000
2012 12 440,796,000
2011 12 422,987,284

 












Bloomberg News for CELGENE:



Google News for CELGENE:

Seeking Alpha - 9 hours ago
Celgene: Great Opportunities For Option Investors
In this article, I'll take a closer look at Celgene's (CELG) situation and explain how you can boost your annualized returns using covered calls.
Motley Fool
Celgene (CELG) Earnings Expected to Grow: Should You Buy?
For Celgene, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish ...
The Hi New Ulm
Buying Celgene
Sorry to be a little behind the curve on the Bristol-Myers Squibb (BMY) deal to acquire Celgene (CELG), but I've been on the road and needed ...
Zacks.com - 13 hours ago
Celgene (CELG) Stock Moves -0.45%: What You Should Know
CELG will be looking to display strength as it nears its next earnings release, which is expected to be January 24, 2019. The company is ...
Seeking Alpha - 6 days ago
Mixed Analyst Attention: Sprint Corporation (S), Celgene ...
... clients that Celgene Corporation (NASDAQ:CELG) is now rated as Outperform. Raymond James also rated CELG as Upgrade on June 13th, ...
FDA Headlines
Bristol-Myers/Celgene: Win-Win Merger
Rarely are mega mergers so appealing as the Bristol-Myers Squibb (BMY) bid to buy Celgene (CELG). The latter biopharma had been beaten ...
Zacks.com - 3 days ago
Bristol-Myers: Fattening Up The Pipeline With Celgene
Bristol-Myers Squibb Co's (BMY) plans to acquire Celgene Corporation (CELG) is game-changing. The total deal is worth around $74 billion ...
Financial Mercury - 9 hours ago
Celgene: Still Upside Left After Deal?
Bristol-Myers Squibb (BMY) agreed to acquire biotech stalwart Celgene (CELG) for just under $75 billion before the bell Thursday. This would ...
Fairfield Current
Celgene (CELG) Alert: Johnson Fistel Investigates Proposed Sale of ...
Celgene (CELG) Alert: Johnson Fistel Investigates Proposed Sale of Celgene Corporation; Are Celgene Shareholders Getting a Fair Deal?
NMSU Nеws
Celgene (CELG) Announces 2019 Financial Guidance
Celgene Corporation (NASDAQ: CELG) today provides a business update, including confirmation that the company achieved its guidance for ...


Back